Sorin Group S.p.A. Announces Results of the Dream Clinical Study

Published: Jun 24, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ATHENS, Greece--(BUSINESS WIRE)--Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the results of the DREAM clinical trial. In this study, the Sleep Apnea Monitoring (SAM) algorithm of Sorin REPLY 200 pacemakers was validated against polysomnography, the gold standard method used to measure the severity of sleep apnea (SA). Initial data show that REPLY 200 with the new SAM algorithm provides reliable screening for the risk of severe SA1.

Help employers find you! Check out all the jobs and post your resume.

Back to news